Skip to Content

Investors

Relevant Facts to the Stock Exchange (Spanish only)

The relevant facts included in this section correspond exactly with those sent to the National Exchange Commission (CNMV) and which have been published on its web site.

If you would like to be alerted when a relevant fact is added to this site, please register for the Email Alert service.

Date Relevant fact Content
24-03-2017 Almirall and Sun Pharma announce the Validation of Regulatory Filing for tildrakizumab for the treatment of moderate-to-severe plaque psoriasis in Europe Almirall and Sun Pharma announce the Validation of Regulatory Filing for tildrakizumab for the treatment of moderate-to-severe plaque psoriasis in Europe
17-03-2017 Appointment of new Chief Scientific Officer and Executive Vice President Research and Development Appointment of new Chief Scientific Officer and Executive Vice President Research and Development
17-03-2017 AstraZeneca enters into a strategic collaboration with Circassia for the development and commercialisation of Tudorza and Duaklir in the US AstraZeneca enters into a strategic collaboration with Circassia for the development and commercialisation of Tudorza and Duaklir in the US
16-03-2017 Almirall and Symatese enter into a global strategic collaboration for the development and commercialization of products in the Aesthetics field Almirall and Symatese enter into a global strategic collaboration for the development and commercialization of products in the Aesthetics field
07-03-2017 Data from Tildrakizumab Clinical Development Program Presented at the 2017 American Academy of Dermatology Meeting Data from Tildrakizumab Clinical Development Program Presented at the 2017 American Academy of Dermatology Meeting
03-03-2017 Proposals for the 2016 AGM (Spanish only) Proposals for the 2016 AGM (Spanish only)
27-02-2017 AGM announcement to be held on May 3, in Barcelona (Spanish only) AGM announcement to be held on May 3, in Barcelona (Spanish only)
27-02-2017 Redemption of the Senior Notes 4.625% due 2021 and signed a Revolving Credit Facility (Spanish only) Redemption of the Senior Notes 4.625% due 2021 and signed a Revolving Credit Facility (Spanish only)
27-02-2017 Almirall announces a webcast presentation and conference call to present FY2016 Financial Results (Spanish only) Almirall announces a webcast presentation and conference call to present FY2016 Financial Results (Spanish only)
04-01-2017 Nombramiento del nuevo Chief Financial Officer y Executive Vice President Finance Nombramiento del nuevo Chief Financial Officer y Executive Vice President Finance
Date Relevant fact Content
21-12-2016 Almirall and Mercachem announce a collaboration for the development of cytokine blockers Almirall and Mercachem announce a collaboration for the development of cytokine blockers
16-12-2016 Almirall: Receipt of 30 million dollars related to milestones from the agreement with AstraZeneca Almirall: Receipt of 30 million dollars related to milestones from the agreement with AstraZeneca
12-12-2016 Almirall: Strategic Collaboration with Nuevolution for the treatment of Dermatology diseases and Psoriatic Arthritis Almirall: Strategic Collaboration with Nuevolution for the treatment of Dermatology diseases and Psoriatic Arthritis
24-11-2016 Almirall reaches an agreement to implement a restructuring plan in Spain Almirall reaches an agreement to implement a restructuring plan in Spain
07-11-2016 Almirall announces a webcast presentation and conference call to present Q1 2016 Financial Results (Spanish only) Almirall announces a webcast presentation and conference call to present Q1 2016 Financial Results (Spanish only)
18-10-2016 Restructuring process in Spain Restructuring process in Spain
03-10-2016 Almirall to Announce Late-Breaking Results for Investigational IL-23p19 inhibitor, Tildrakizumab Almirall to Announce Late-Breaking Results for Investigational IL-23p19 inhibitor, Tildrakizumab
28-09-2016 Almirall announces positive phase III results showing efficacy of LAS41008 (dimethyl fumarate), a new systemic oral drug for patients with chronic plaque psoriasis Almirall announces positive phase III results showing efficacy of LAS41008 (dimethyl fumarate), a new systemic oral drug for patients with chronic plaque psoriasis
28-07-2016 Almirall has announced a webcast presentation and conference call to present the License Agreement of Tildrakizumab for Psoriasis in Europe (Spanish only) Almirall has announced a webcast presentation and conference call to present the License Agreement of Tildrakizumab for Psoriasis in Europe (Spanish only)
27-07-2016 Almirall and Sun Pharma enter into a License Agreement for Tildrakizumab in Europe for Psoriasis Almirall and Sun Pharma enter into a License Agreement for Tildrakizumab in Europe for Psoriasis
26-07-2016 Almirall has announced a webcast presentation and conference call to present the H1 2016 Financial Results (Spanish only) Information on H1 2016 Financial Results (Spanish only)
22-07-2016 Almirall announces a global licensing agreement with Patagonia Pharmaceuticals for congenital ichthyosis Almirall announces a global licensing agreement with Patagonia Pharmaceuticals for congenital ichthyosis
17-06-2016 Almirall announces changes in the composition of the management board (Spanish only) Almirall announces changes in the composition of the management board (Spanish only)
11-05-2016 Appointment of a member of the Board of Directors (Spanish only) Appointment of a member of the Board of Directors (Spanish only)
09-05-2016 Almirall announces a webcast presentation and conference call to present Q1 2016 Financial Results (Spanish only) Almirall announces a webcast presentation and conference call to present Q1 2016 Financial Results (Spanish only)
15-03-2016 Almirall announces transfer of the affiliate in Mexico Almirall announces transfer of the affiliate in Mexico
07-03-2016 Notification of the member state of origin (Spanish Only) Notification of the member state of origin (Spanish Only)
22-02-2016 AGM announcement to be held on May 6, in Barcelona (Spanish only) AGM announcement to be held on May 6, in Barcelona (Spanish only)
22-02-2016 Almirall announces a webcast presentation and conference call to present FY2015 Financial Results (Spanish only) Almirall announces a webcast presentation and conference call to present FY2015 Financial Results (Spanish only)
22-02-2016 Modification of the Board of Director´s Regulations and internal Code of Conduct in the Securities Market (Spanish only) Modification of the Board of Director´s Regulations and internal Code of Conduct in the Securities Market (Spanish only)
25-01-2016 Corporate Resolutions of the Extraordinary General Meeting of Shareholders held on 22 January 2016 (Spanish only) Corporate Resolutions of the Extraordinary General Meeting of Shareholders held on 22 January 2016 (Spanish only)
12-01-2016 34th Annual J.P Morgan Healthcare Conference 2016 34th Annual J.P Morgan Healthcare Conference 2016
04-01-2016 Almirall exercises call option to acquire 100% of ThermiGen LLC Almirall exercises call option to acquire 100% of ThermiGen LLC
Date Relevant fact Content
10-12-2015 Announcements and agreements of shareholders general meetings (Spanish Only) Calling an Extraordinary General Shareholders´ Meeting (Spanish Only)
30-11-2015 Almirall reaches an agreement to acquire 100% of Poli Group Holding S.R.L Almirall reaches an agreement to acquire 100% of Poli Group Holding S.R.L
02-11-2015 Senior notes issued on 27 March 2014 - "Offer to Purchase" Senior notes issued on 27 March 2014 - "Offer to Purchase"
27-10-2015 2015 guidance upgraded due to operational outperformance and duaklir® launch in south korea 2015 guidance upgraded due to operational outperformance and duaklir® launch in south korea
27-10-2015 Divestment of constella®/linzess® to allergan Divestment of constella®/linzess® to allergan
28-07-2015 Almirall announced a webcast presentation and a conference call to present the H1 2015 Financial Results (Spanish only) Almirall´s webcast and conference call details to present H1 2014 financial results
21-04-2015 Almirall reaches an agreement to implement a reorganization process in the R&D team in Spain Almirall reaches an agreement to implement a reorganization process in the R&D team in Spain
18-03-2015 Reorganization R&D Spain Reorganization process in the R&D team in Spain
05-03-2015 Modification of venue of the annual general meeting Modification of venue of the annual general meeting
23-02-2015 AGM announcement to be held on May 8th, in Barcelona AGM announcement to be held on May 8th, in Barcelona (Spanish only)
23-02-2015 Almirall announces a webcast presentation and a conference call to present FY2014 Financial Results (Spanish only) Almirall announces a webcast presentation and a conference call to present FY2014 Financial Results (Spanish only)
05-02-2015 Almirall: Notification about the aclidinium bromide franchise in the USA and Canada Almirall: Notification about the aclidinium bromide franchise in the USA and Canada
26-01-2015 Significant Fact Financial Results Calendar 2015 Significant Fact Financial Results Calendar 2015
12-01-2015 Clarification about the financial guideline (Spanish only) Clarification about the financial guideline
Date Relevant fact Content
19-12-2014 Almirall : Notification about news arisen concerning a takeover bid are not true (Spanish only) Almirall: Notification about news arisen concerning a takeover bid are not true (Spanish only)
24-11-2014 Aclidinium + Formoterol combination approved in Europe Aclidinium + Formoterol combination approved in European Union by the European Commission
10-11-2014 Almirall announced a webcast presentation and a conference call to present the Q3 2014 Financial Results (Spanish only) Almirall´s webcast and conference call details to present Q3 2014 financial results
07-11-2014 Agreements reached during the Extraordinary General Meeting of Shareholders (Spanish only) Almirall announces the Agreements reached in today's EGM held today November 7th, 2014 (Spanish only)
03-11-2014 Almirall announces the closure of the deal between Almirall and AstraZeneca Almirall announces the closure of the deal between Almirall and AstraZeneca
26-09-2014 R&D results obtained: licences, patents and brands Positive voting by the CHMP in favour of Aclidinium/Formoterol combination in Europe
25-09-2014 Announcements and agreements of shareholders general meetings (Spanish Only) Calling an Extraordinary General Shareholders´ Meeting (Spanish Only)
30-07-2014 Almirall announces a strategic transaction with AstraZeneca (Spanish only) Almirall announces a strategic transaction with AstraZeneca
29-07-2014 Almirall announced a webcast presentation and a conference call to present the H1 2014 Financial Results (Spanish only) Almirall´s webcast and conference call details to present H1 2014 financial results
28-07-2014 Changes in the composition of the Board (in Spanish only) Changes in the composition of the Board (in Spanish only)
12-05-2014 Almirall announced a webcast presentation and a conference call to present the Q1 2014 Financial Results (Spanish only) Almirall´s webcast and conference call details to present Q1 2014 financial results
09-05-2014 Agreements reached during the Ordinary General Meeting of Shareholders (Spanish only) Almirall announces the Agreements reached in today's AGM (Spanish only)
09-04-2014 Update regarding the aclidinium + formoterol combination in the US Update regarding the aclidinium + formoterol combination in the US
27-03-2014 Almirall announces the successful closing and payment of their Corporate Bonds Almirall announces the successful closing and payment of their Corporative Bonds
19-03-2014 Price Fixed and Credit Ratings for Almirall´s Corporate Bonds Fixed and Credit Ratings for Almirall´s Corporate Bonds
17-03-2014 Almirall announces their intention to issue Corporate Bonds Almirall announces their intention to issue Corporate Bonds
07-03-2014 Agreements reached during the Extraordinary General Meeting of Shareholders (Spanish only) Shareholders agree that the Board of Directors may issue bonds during the following 5 years with a maximum value of 375,000,000 euros. (Spanish only)
24-02-2014 Información sobre resultados Almirall announced a webcast presentation and a conference call to present the FY 2013 Financial Results
04-02-2014 A Personnel matters Almirall agrees with worker Union on Labor Restructuring (Spanish only)
30-01-2014 Announcements and agreements of shareholders general meetings (Spanish only) Calling an Extraordinary Annual General Meeting (Spanish only)
23-01-2014 Other on Financial instrument Almirall´s main shareholder private placement process completed (Spanish only)
22-01-2014 Other on Financial instrument Almirall main shareholder aiming to complete private placement of 8.7 million share
02-01-2014 Transmissions and purchases of capital undertakings (Spanish only) Almirall seals the acquisition of Aqua Pharmaceuticals
Date Relevant fact Content
17-12-2013 Almirall announced a webcast presentation and a conference call to detail the acquisition of Aqua Pharmaceuticals (Spanish Only) Almirall reaches an agreement to acquire Aqua Pharmaceuticals, a US- based specialty dermatology company
05-12-2013 Plan de Reorganización en Europa Almirall announces a reorganization program affecting the group in Europe
11-11-2013 Información sobre los resultados Almirall announced a webcast presentation and a conference call to present the Q3 2013 Financial Results
08-11-2013 Composición del Consejo de Administración Almirall announced the appointment of Mr Joan Figueras Carreras as Vice-Secretary non-member of the Board of Directors
04-11-2013 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announced the submission of a Marketing Authorisation Application to the European Medicines Agency for the combination of aclidinium bromide and formoterol
15-08-2013 I+D: resultados obtenidos, licencias, patentes y marcas Almirall and Forest decide to delay the IND Filing of the combination aclidinium + formoterol
29-07-2013 Información sobre resultados Almirall announced a webcast presentation and a conference call to present the Half Year 2013 Financial Results
26-06-2013 I+D: resultados obtenidos, licencias, patentes y marcas Announcement of US$15Mill milestone income linked to Phase III Combo of aclidinium and formoterol
14-06-2013 Anuncio Convocatorias y Acuerdos de Juntas Listing of new shares (only in Spanish)
03-06-2013 Información sobre dividendos Closing of the negotiation process related to the Scrip Dividend
13-05-2013 Anuncio Convocatorias y Acuerdos de Juntas Complementary informative document - Scrip Dividend (only in Spanish)
07-05-2013 Información sobre resultados Almirall announced a webcast presentation and a conference call to present the Q1 2013 Financial Results
06-05-2013 Información sobre dividendos Informative document about the Scrip dividend
03-05-2013 Información sobre dividendos Almirall informs about the Scrip Dividend Calendar
03-05-2013 Anuncio Convocatorias y Acuerdos de Juntas Almirall informs about the Agreements taken in today's AGM
02-05-2013 I+D: Resultados obtenidos, licencias, patentes y marcas Positive Phase III combo results from its 2nd Study (aclidinium + formoterol)
16-04-2013 pdf I+D: Resultados obtenidos, licencias, patentes y marcas Positive Phase III combo results from its 1st Study (aclidinium + formoterol)
18-03-2013 I+D: Resultados obtenidos, licencias, patentes y marcas Almirall announces positive results from aclidinium development in Japan
26-02-2013 Convocatorias y acuerdos de Juntas y Asambleas generales Amending relevant fact issued yesterday (no. 18274) due to a typing error in the numbering of the agenda of the Annual General Meeting Notice
25-02-2013 Almirall announced a webcast presentation and a conference call to present the FY 2012 Financial Results Información sobre resultados
25-02-2013 AGM announcement to be held on May 3rd, in Barcelona AGM announcement to be held on May 3rd, in Barcelona
23-01-2013 Convocatoria de reunión o actos informativos Almirall announced today its financial calendar for 2013
17-01-2013 I+D: resultados obtenidos, licencias, patentes y marcas Launch of Eklira® Genuair® in Spain and other European countries
Date Relevant fact Content
11-12-2012 I+D: resultados obtenidos, licencias, patentes y marcas Almirall and Forest Laboratories announce commercial availability of Tudorza" Pressair" in U.S. pharmacies
28-11-2012 I+D: resultados obtenidos, licencias, patentes y marcas Constella® (linaclotide) approved in Europe for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Adults
19-11-2012 Composición del Consejo de Administración Almirall appoints Karin Louise Dorrepaal as new independent board member
23-10-2012 Transmisiones y adquisiciones de participaciones societarias Almirall buys share equity in the biotech company AB-Biotics
22-10-2012 Anuncio Convocatorias y Acuerdos de Juntas Announcement of the approved social agreements in the Extraordinary AGM held last Friday, October 19th 2012
21-09-2012 I+D: resultados obtenidos, licencias, patentes y marcas Linaclotide receives positive CHMP opinion for the treatment of IBS-C
27-07-2012 Anuncio Convocatorias y Acuerdos de Juntas Announcement of next Extraordinary AGM on October 19th 2012 in Barcelona
25-07-2012 I+D: resultados obtenidos, licencias, patentes y marcas Announcement of two milestones to be perceived linked to aclidinium approvals in EU and US
24-07-2012 I+D: resultados obtenidos, licencias, patentes y marcas Almirall, S.A. and Forest Laboratories, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Tudorza" Pressair" (aclidinium bromide inhalation powder) for the treatment of COPD.
24-07-2012 I+D: resultados obtenidos, licencias, patentes y marcas Aclidinium approved in Europe
08-06-2012 Anuncio Convocatorias y Acuerdos de Juntas HR Admision a cotizacion nuevas acciones (only in Spanish)
30-05-2012 Anuncio Convocatorias y Acuerdos de Juntas HR Cierre del periodo de negociacion (only in Spanish)
11-05-2012 Anuncio Convocatorias y Acuerdos de Juntas Complementary Informative document - Scrip dividend (only in Spanish)
07-05-2012 Anuncio Convocatorias y Acuerdos de Juntas Informative document - Scrip dividend (only in Spanish)
04-05-2012 Anuncio Convocatorias y Acuerdos de Juntas Agreements AGM2012
04-05-2012 Anuncio Convocatorias y Acuerdos de Juntas Scrip Dividend Calendar
04-05-2012 Anuncio Convocatorias y Acuerdos de Juntas Appointment and Committees
29-03-2012 I+D: resultados obtenidos, licencias, patentes y marcas Almirall and Forest Laboratories announce FDA has extended the review period for Aclidinium Bromide
27-03-2012 Anuncio Convocatorias y Acuerdos de Juntas Notice and agenda modification
26-03-2012 I+D: resultados obtenidos, licencias, patentes y marcas Almirall and Menarini sign a commercial alliance for aclidinium in most EU and other European countries
27-02-2012 Anuncio Convocatorias y Acuerdos de Juntas Announcement of next AGM on May 4th 2012 in Barcelona
24-02-2012 I+D: resultados obtenidos, licencias, patentes y marcas Almirall & Forest announce positive FDA Advisory Committee for aclidinium
09-02-2012 I+D: resultados obtenidos, licencias, patentes y marcas Almirall to co-promote Bayer's anticoagulant Rivaroxaban in Spain
Date Relevant fact Content
16-11-2011 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces the start of Phase III for aclidinium and formoterol in COPD
24-10-2011 I+D: resultados obtenidos, licencias, patentes y marcas Almirall presents full results from two pivotal Phase III clinical trials of linaclotide at the 19th European Gastroenterology Week (UEGW) in Stockholm
19-10-2011 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces a co-promotion agreement with Lundbeck for escitalopram in Italy
04-10-2011 Planes estratégicos, previsiones y presentaciones Almirall announces a guidance update for 2011 and 2012
03-10-2011 I+D: resultados obtenidos, licencias, patentes y marcas Almirall launches roflumilast in Spain
29-09-2011 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces regulatory filing of linaclotide for the treatment of irritable bowel syndrome with constipation in Europe
29-09-2011 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces a licensing agreement with Nycomed for ebastine in China and other key Southeast Asia markets
27-09-2011 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces that COPD patients experienced benefits from the first dose when treated with aclidinium, as shown in the ATTAIN Phase III study
26-08-2011 Transmisiones y adquisiciones de participaciones societarias Almirall publishes a communication received from the shareholders of its intention to initiate a process to purchase up to 1.5% stake in Almirall in the next 6 months
27-07-2011 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces the regulatory submission of aclidinium bromide for the treatment of COPD in Europe
26-07-2011 Composición del consejo de administración Almirall announces changes in the Board composition and in the Internal Code of Conduct (Spanish)
05-07-2011 I+D: resultados obtenidos, licencias, patentes y marcas Almirall strengthens its German business with two new products: Sativex® and Actikerall®
30-06-2011 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces theregulatory submission of aclidinium bromide for the treatment of COPD in the USA
08-06-2011 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces that Sativex® has been approved in Denmark for the treatment of spasticity due to Multiple Sclerosis (MS)
06-06-2011 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces that Actikerall® is launched in the UK for the treatment of actinic keratosis, including grade I and II
26-05-2011 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces Sativex® has been approved in Germany for the treatment of spasticity due to Multiple Sclerosis
20-05-2011 Composición de otros órganos de gestión y control Almirall announces the renewal of the members of the Auditing Committee and the Appointment and Commission Committee
09-05-2011 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces that is presenting additional data from ATTAIN (Phase III study) of aclidinium bromide at the annual ATS 2011
09-05-2011 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces Actikerall® receives positive recommendation and process enters national approval phase in 7 European countries
06-05-2011 Acuerdos de Junta Announcement of dividend approval and other agreements reached at today's AGM
05-05-2011 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces a commercialization agreement with Nycomed for roflumilast in Spain
22-03-2011 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces that Sativex® is recommended for approval in all six European countries
17-03-2011 Composición de otros órganos de gestión y control Almirall announces the appointment of a new CEO
14-03-2011 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces the launch of Sativex® in Spain to treat spasticity in multiple sclerosis
28-02-2011 Anuncio Convocatorias y Acuerdos de Juntas Announcement of next AGM on May 6th 2011 in Barcelona
24-02-2011 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces a licensing agreement in Japan with aclidinium bromide
16-02-2011 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces that the reimbursement for Sativex® in Spain has been granted, for the treatment of spasticity in multiple sclerosis
04-01-2011 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces positive phase III results of aclidinium bromide
Date Relevant fact Content
23-11-2010 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces that Sativex® enters Phase III clinical programme in oncological pain "
18-11-2010 Composición de otros órganos de gestión y control Almirall announces a change in the composition of the Management
05-11-2010 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces a milestone payment to Ironwood after the positive results from the two Phase III trials of linaclotide
01-11-2010 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces positive results from the second Phase III trial of linaclotide in patients with irritable bowel syndrome with constipation
29-10-2010 I+D: resultados obtenidos, licencias, patentes y marcas Almirall reports preliminary topline results from the ACCORD COPD II Phase III study of aclidinium bromide in Chronic Obstructive Pulmonary Disease (COPD)
13-09-2010 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces positive results from a phase 3 trial with linaclotide in patients with irritable bowel syndrome with constipation
28-07-2010 Otros sobre negocio y situación financiera Almirall announces that Sativex® receives regulatory authorisation in Spain
26-07-2010 Acuerdos estratégicos con terceros Almirall signs a co-promotion agreement with Pfizer to commercialise Conbriza® in Spain, a new therapeutic option to treat osteoporosis
23-07-2010 Otros sobre operaciones corporativas Almirall announces an agreement with Meda
15-06-2010 Acuerdos estratégicos con terceros Almirall announces an international agreement with Basilea to commercialize Toctino® (alitretinoin) for severe chronic hand eczema
01-06-2010 Otros sobre negocio y situación financiera Almirall updates 2010 financial guidance
20-05-2010 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces that regulators in UK and Spain confirm Sativex® is approvable
14-05-2010 Acuerdos de Junta Announcement of dividend approval and other agreements reached at today's AGM
11-05-2010 I+D: resultados obtenidos, licencias, patentes y marcas Almirall to present data from studies of Eklira® (aclidinium bromide) in Chronic Obstructive Pulmonary Disease (COPD) and LAS100977 in asthma
10-05-2010 Otros Hechos Relevantes Information related to the Long term incentive plan for Executives
05-03-2010 Anuncio Convocatorias y Acuerdos de Juntas Announcement of next AGM on May 14th 2010 in Barcelona
25-02-2010 Otros sobre Gobierno Corporativo Announcement of the approvals taken by the Board of Directors related to the Art. 116 of the Spanish Exchange Law report, the report on the Remuneration Policy adn the Audit Commitee Report 2009
08-02-2010 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announced silodosin has been approved by the European Commission
26-01-2010 I+D: resultados obtenidos, licencias, patentes y marcas Almirall announces that it has strengthened its focus to the twice-daily dosing of Eklira® in Chronic Obstructive Pulmonary Disease (COPD)
07-01-2010 I+D: resultados obtenidos, licencias, patentes y marcas Announcement of positive results from the ACCORD COPD I Phase III study of aclidinium bromide in Chronic Obstructive Pulmonary Disease (COPD)
Date Relevant fact Content
17-12-2009 I+D: resultados obtenidos, licencias, patentes y marcas Announcement of an agreement between Almirall and Forest Laboratories to expand respiratory collaboration
10-11-2009 Otros Hechos Relevantes Announcement of a US$ 15 M equity investment in Ironwood Pharmaceuticals for linaclotide
20-10-2009 Otros Hechos Relevantes Announcement of Eklira update: Positive results in a comparative trial and announcement of new Phase III studies
09-09-2009 Otros Hechos Relevantes Announcement of the filing of once daily aclidinium bromide for COPD in Europe in early 2010
30-07-2009 Avance de Resultados de Sociedades Emisoras 1st Half 2009 Financial Results Presentation to analysts and investors
30-07-2009 Avance de Resultados de Sociedades Emisoras 1st Half 2009 Financial results presentation
01-07-2009 Otros Hechos Relevantes Announcement of the change to our company name from Laboratorios Almirall, S.A. to Almirall, S.A.
22-05-2009 Acuerdos de Junta Announcement of dividend approval and other agreements reached at today's AGM.
04-05-2009 Otros Hechos Relevantes Announcement of a pan-European licensing-in agreement with Ironwood for linaclotide, a novel gastrointestinal compound
30-04-2009 Otros Hechos Relevantes Announcement of an update of the respiratory pipeline
03-04-2009 Otros Hechos Relevantes Announcement of a co-marketing agreement with Recordati for the marketing of silodosin in Spain, a new compound for benign prostatic hyperplasia
01-04-2009 Otros Hechos Relevantes Announcement of a milestone payment of £8 million (approx. ¬ 8,6 million), after the positive results in the Sativex's phase III study, to its partner GW Pharmaceuticals plc. and for which Almirall has the marketing rights throught Europe, expect in the United Kingdom
12-03-2009 Otros Hechos Relevantes Announcement of positive preliminary phase III results of Sativex for the treatment of spasticity, for which Almirall has the marketing rights throught Europe, expect in the United Kingdom
06-03-2009 Otros Hechos Relevantes Announcement of an update on the Aclidinium Bromide Clinical Development Program
27-02-2009 Informe Anual Gobierno Corporativo 2008 Corporate Governance Annual Report
27-02-2009 Avance de Resultados de Sociedades Emisoras 2nd Half 2008 Financial results information
27-02-2009 Anuncio Convocatorias y Acuerdos de Juntas Announcement of next AGM on May 22nd 2009 in Barcelona
13-01-2009 Otros Hechos Relevantes Announcement of the sale of 13 products for 19.1 million euros